Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Adenocarcinoma × aflutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 24 Brain Neoplasms 4 Adenocarcinoma of Lung 4 NSCLC 3 Meningeal Carcinomatosis 3 Lung Neoplasms 2 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Oxaliplatin 31 Fluorouracil 23 Gemcitabine 19 Leucovorin 18 Docetaxel 18 pembrolizumab 17 Capecitabine 15 Radiotherapy 13 Irinotecan 13 Bevacizumab 11 Cisplatin 10 Nivolumab 8 130-nm albumin-bound paclitaxel 8 Cyclophosphamide 7 Trastuzumab 6 Radiosurgery 6 Paclitaxel 6 Albumin-Bound Paclitaxel 6 S 1 (combination) 5 Metformin 5 Erlotinib Hydrochloride 5 Carboplatin 5 Blood Specimen Collection 5 Taxes 4 Sunitinib 4 Sorafenib 4 Pemetrexed 4 Esophagectomy 4 Chemoradiotherapy 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡